Bifogade filer
PDF
Kurs
+0,45%
Likviditet
0,20 MSEK
Kalender
| Tid* | ||
| 2024-02-21 | - | Bokslutskommuniké 2023 |
| 2023-11-13 | - | Extra Bolagsstämma 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-04 | - | Kvartalsrapport 2023-Q2 |
| 2023-07-03 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2023-06-30 | - | Årsstämma |
| 2023-05-17 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-22 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-25 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2022-05-24 | - | Årsstämma |
| 2022-04-27 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-11-09 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-07-15 | - | Extra Bolagsstämma 2021 |
| 2021-05-04 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-29 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2021-04-28 | - | Årsstämma |
| 2021-02-16 | - | Bokslutskommuniké 2020 |
| 2020-11-10 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-29 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2020-04-28 | - | Årsstämma |
| 2020-03-02 | - | Extra Bolagsstämma 2020 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-08 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-29 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-15 | - | Kvartalsrapport 2019-Q1 |
| 2019-05-15 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2019-05-14 | - | Årsstämma |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-07 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-27 | - | Kvartalsrapport 2018-Q2 |
| 2018-06-04 | - | X-dag ordinarie utdelning IRRAS 0.00 SEK |
| 2018-05-29 | - | Kvartalsrapport 2018-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Stockholm, August 3, 2023 - The Board of Directors of IRRAS AB has today resolved on a revision of the company's financial outlook. The company reiterates its previously communicated financial targets but has decided to reassess the time horizon.
As a result of its recently announced change in commercial strategy to close its wholly owned European subsidiaries and prioritize its activities in the United States market, the company has decided that additional time is required to assess the full impact of these changes and the associated impact on the time horizon of its financial outlook. The previously communicated financial targets remain but, for these reasons, the company currently chooses to refrain from publishing a specific timeline.
Financial outlookRevenue is expected to, long term, exceed SEK 350 million per year.
Gross margin is expected to, long term, exceed 60%.
This disclosure contains information that IRRAS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-08-2023 07:55 CET.
Will Martin
President and Chief Executive Officer
ir@irras.com